Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Trento – page 6

79 clinical trials in Trento, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Trento at a glance
79
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

79 trials in Trento

Open in trial search

Philadelphia positive acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Non-small cell lung cancer

Not recruiting

Study on Bevacizumab and Erlotinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Plasma cell myeloma

Not recruiting

Study of Daratumumab with Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Prostate cancer metastatic

Not recruiting

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Prostate cancer metastatic

Not recruiting

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Prostate cancer metastatic

Not recruiting

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Breast cancer

Not recruiting

Study on Anastrozole, Letrozole, Exemestane, and Tamoxifen for Women Aged 70+ with Early Stage Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Anastrozole
  • Sponsor:University Of Florence

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Trento

What the registry says about research in the country

01 Oncology - Prostate Cancer

Innovative clinical trials focusing on metastatic castration-resistant prostate cancer, evaluating new therapeutic combinations and treatment sequences.

  • Novel hormone therapies
  • Targeted drug combinations
  • Radiation therapy approaches

Studies are examining both early-stage and advanced disease management strategies.

02 Oncology - Breast Cancer

Research initiatives exploring treatments for HER2-positive and HER2-low breast cancer, including studies for both early-stage and metastatic disease.

  • Targeted therapies
  • Hormone receptor studies
  • Novel drug combinations

Particular focus on personalized treatment approaches for different breast cancer subtypes.

03 Oncology - Other Cancers

Comprehensive studies investigating treatments for lung cancer, melanoma, and urothelial cancer.

  • Immunotherapy approaches
  • Maintenance therapies
  • Targeted treatments

Focus on improving survival rates and quality of life for patients with various cancer types.

04 Cardiovascular Medicine

Innovative research in acute myocardial infarction management and prevention, with emphasis on emergency interventions.

  • Self-administered treatments
  • Emergency care protocols
  • Preventive strategies

Studies aim to improve rapid response and outcomes in cardiac emergencies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.